by Adam | Oct 22, 2020 | News
PROVIDENCE, RI, October 22, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) and CUBRC, Inc. (“CUBRC”) announced today that they have been awarded a two-year, $1.1 million contract from the Office of Generic Drugs (OGD) in the Center of Drug Evaluation and Research...
by Adam | Jun 8, 2020 | News
PROVIDENCE, RI, June 8, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) a Rhode Island-based company and recognized leader in the field in the field of immunogenicity assessment today announced it has licensed its advanced in silico toolkit for biologics...
by Adam | Jun 2, 2020 | News
Bilthoven, The Netherlands, Providence, R.I., USA, 2 June 2020 – Intravacc, one of the world’s leading translational research and development vaccine institutes, with an extensive track record in developing viral and bacterial vaccines, and EpiVax, a...
by Annie De Groot | Feb 3, 2020 | Events
Dr. Anne De Groot will be going to Lisbon, Portugal to attend the European Immunogenicity Platform Symposium from 17-19th Feb. While there, she will be giving a talk on EpiVax’s immunoinformatics platform on Day 2, 18Feb at 2:30PM. The talk will focus on...
